134 related articles for article (PubMed ID: 31442762)
1. ipcwswitch: An R package for inverse probability of censoring weighting with an application to switches in clinical trials.
Grafféo N; Latouche A; Le Tourneau C; Chevret S
Comput Biol Med; 2019 Aug; 111():103339. PubMed ID: 31442762
[TBL] [Abstract][Full Text] [Related]
2. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
Latimer NR; Abrams KR; Siebert U
BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
[TBL] [Abstract][Full Text] [Related]
3. The net benefit for time-to-event outcome in oncology clinical trials with treatment switching.
Fukuda M; Sakamaki K; Oba K
Clin Trials; 2023 Dec; 20(6):670-680. PubMed ID: 37455538
[TBL] [Abstract][Full Text] [Related]
4. Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias?
Rimawi M; Hilsenbeck SG
J Clin Oncol; 2012 Feb; 30(4):453-8. PubMed ID: 22215751
[TBL] [Abstract][Full Text] [Related]
5. Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator.
Willems S; Schat A; van Noorden MS; Fiocco M
Stat Methods Med Res; 2018 Feb; 27(2):323-335. PubMed ID: 26988930
[TBL] [Abstract][Full Text] [Related]
6. Adjusting overall survival for treatment switches: commonly used methods and practical application.
Watkins C; Huang X; Latimer N; Tang Y; Wright EJ
Pharm Stat; 2013; 12(6):348-57. PubMed ID: 24136868
[TBL] [Abstract][Full Text] [Related]
7. The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.
Dong G; Mao L; Huang B; Gamalo-Siebers M; Wang J; Yu G; Hoaglin DC
J Biopharm Stat; 2020 Sep; 30(5):882-899. PubMed ID: 32552451
[TBL] [Abstract][Full Text] [Related]
8. Using inverse-weighting in cost-effectiveness analysis with censored data.
Willan AR; Lin DY; Cook RJ; Chen EB
Stat Methods Med Res; 2002 Dec; 11(6):539-51. PubMed ID: 12516988
[TBL] [Abstract][Full Text] [Related]
9. Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study).
Yoshida M; Matsuyama Y; Ohashi Y;
Clin Trials; 2007; 4(4):318-28. PubMed ID: 17848493
[TBL] [Abstract][Full Text] [Related]
10. Adjusting win statistics for dependent censoring.
Dong G; Huang B; Wang D; Verbeeck J; Wang J; Hoaglin DC
Pharm Stat; 2021 May; 20(3):440-450. PubMed ID: 33247544
[TBL] [Abstract][Full Text] [Related]
11. Randomized Controlled Trials 7: On Contamination and Estimating the Actual Treatment Effect.
Parfrey PS
Methods Mol Biol; 2021; 2249():307-318. PubMed ID: 33871851
[TBL] [Abstract][Full Text] [Related]
12. On logistic regression with right censored data, with or without competing risks, and its use for estimating treatment effects.
Blanche PF; Holt A; Scheike T
Lifetime Data Anal; 2023 Apr; 29(2):441-482. PubMed ID: 35799026
[TBL] [Abstract][Full Text] [Related]
13. Selection Bias Due to Loss to Follow Up in Cohort Studies.
Howe CJ; Cole SR; Lau B; Napravnik S; Eron JJ
Epidemiology; 2016 Jan; 27(1):91-7. PubMed ID: 26484424
[TBL] [Abstract][Full Text] [Related]
14. Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests.
Robins JM; Finkelstein DM
Biometrics; 2000 Sep; 56(3):779-88. PubMed ID: 10985216
[TBL] [Abstract][Full Text] [Related]
15. Improved two-stage estimation to adjust for treatment switching in randomised trials: g-estimation to address time-dependent confounding.
Latimer NR; White IR; Tilling K; Siebert U
Stat Methods Med Res; 2020 Oct; 29(10):2900-2918. PubMed ID: 32223524
[TBL] [Abstract][Full Text] [Related]
16. Adjustment for treatment changes in epilepsy trials: A comparison of causal methods for time-to-event outcomes.
Dodd S; Williamson P; White IR
Stat Methods Med Res; 2019 Mar; 28(3):717-733. PubMed ID: 29117780
[TBL] [Abstract][Full Text] [Related]
17. Comparison of baseline covariate adjustment methods for restricted mean survival time.
Hanada K; Moriya J; Kojima M
Contemp Clin Trials; 2024 Mar; 138():107440. PubMed ID: 38228232
[TBL] [Abstract][Full Text] [Related]
18. Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation.
Jönsson L; Sandin R; Ekman M; Ramsberg J; Charbonneau C; Huang X; Jönsson B; Weinstein MC; Drummond M
Value Health; 2014 Sep; 17(6):707-13. PubMed ID: 25236994
[TBL] [Abstract][Full Text] [Related]
19. Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.
Kubo Y; Sterling LR; Parfrey PS; Gill K; Mahaffey KW; Gioni I; Trotman ML; Dehmel B; Chertow GM
Pharm Stat; 2015; 14(3):242-51. PubMed ID: 25851955
[TBL] [Abstract][Full Text] [Related]
20. Comparison of dynamic treatment regimes via inverse probability weighting.
Hernán MA; Lanoy E; Costagliola D; Robins JM
Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):237-42. PubMed ID: 16611197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
